ANNAPOLIS – Biodefense firm PharmAthene will issue two-year, 10 percent unsecured senior convertible notes and common stock purchase warrants in a private placement that will total approximately $19.3 million. The financing will eliminate short-term debt and strengthen the company’s balance sheet.

See full release.